Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Spero Therapeutics, Inc. (SPRO) had Return on Tangible Equity of 14.52% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$66.80M |
|
$8.57M |
|
-- |
|
$66.80M |
|
$60.49M |
|
$6.31M |
|
$2.52M |
|
$8.83M |
|
$8.83M |
|
$8.57M |
|
$8.57M |
|
$8.57M |
|
$8.57M |
|
$6.31M |
|
$6.31M |
|
56.02M |
|
59.04M |
|
$0.15 |
|
$0.15 |
|
| Balance Sheet Financials | |
$67.29M |
|
-- |
|
$1.63M |
|
$68.92M |
|
$8.87M |
|
-- |
|
$1.03M |
|
$9.90M |
|
$59.02M |
|
$59.02M |
|
$59.02M |
|
56.41M |
|
| Cash Flow Statement Financials | |
$-12.62M |
|
-- |
|
-- |
|
$52.89M |
|
$40.27M |
|
$-12.62M |
|
$4.33M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.59 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
9.45% |
|
9.45% |
|
9.45% |
|
13.22% |
|
12.83% |
|
$-12.62M |
|
-- |
|
-- |
|
-- |
|
0.97 |
|
-- |
|
2.63 |
|
138.71 |
|
14.52% |
|
|
Return on Tangible Equity |
14.52% |
12.44% |
|
14.52% |
|
$1.05 |
|
$-0.21 |
|
$-0.21 |
|